Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GA-GCB transition study in type 1 Gaucher disease previously treated with imiglucerase
2006-006304-11Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2007
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of velaglucerase alfa in Gaucher disease type 1 (GD1), sponsored by Takeda. Primary endpoint: Safety of transition from imiglucerase to GA-GCB. Started Feb 2007; status: completed.
02
Drugs
velaglucerase alfa
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2006-006304-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006304-11.